Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | ONCOLOGY//CELL BIOLOGY//BIOCHEMISTRY & MOLECULAR BIOLOGY | 2934640 |
| 266 | 3 | NUCL MED//RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING//JOURNAL OF NUCLEAR MEDICINE | 45145 |
| 396 | 2 | RADIOIMMUNOTHERAPY//NUCLEAR MEDICINE AND BIOLOGY//RADIOPHARMACEUTICALS | 17258 |
| 25897 | 1 | EGF DEXTRAN//PROSTHETIC RADIOIODINATION//IN VIVO DEIODINATION | 290 |
Terms with highest relevance score |
| rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|---|
| 1 | EGF DEXTRAN | authKW | 347769 | 1% | 80% | 4 |
| 2 | PROSTHETIC RADIOIODINATION | authKW | 326035 | 1% | 100% | 3 |
| 3 | IN VIVO DEIODINATION | authKW | 217357 | 1% | 100% | 2 |
| 4 | INDIRECT RADIOBROMINATION | authKW | 217357 | 1% | 100% | 2 |
| 5 | N 4 ISOTHIOCYANATOBENZYL 2 3 TRIBUTYLSTANNYLPHENYL ACETAMIDE IBPA | authKW | 217357 | 1% | 100% | 2 |
| 6 | N SUCCINIMIDYL 4 IODOBENZOATE | authKW | 217357 | 1% | 100% | 2 |
| 7 | POLYHEDRAL BORON ANIONS | authKW | 217357 | 1% | 100% | 2 |
| 8 | ANTIBODY BINDING PARAMETERS | authKW | 195618 | 1% | 60% | 3 |
| 9 | BIOMED RADIAT SCI | address | 176419 | 6% | 10% | 17 |
| 10 | RADIOIODINATION | authKW | 173424 | 6% | 9% | 18 |
Web of Science journal categories |
| chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | Radiology, Nuclear Medicine & Medical Imaging | 1947 | 32% | 0% | 93 |
| 2 | Biochemical Research Methods | 959 | 20% | 0% | 57 |
| 3 | Oncology | 382 | 20% | 0% | 59 |
| 4 | Nuclear Science & Technology | 199 | 8% | 0% | 24 |
| 5 | Chemistry, Organic | 175 | 12% | 0% | 36 |
| 6 | Biochemistry & Molecular Biology | 171 | 23% | 0% | 68 |
| 7 | Chemistry, Analytical | 159 | 11% | 0% | 33 |
| 8 | Chemistry, Medicinal | 142 | 7% | 0% | 21 |
| 9 | Chemistry, Inorganic & Nuclear | 81 | 7% | 0% | 20 |
| 10 | Medicine, Research & Experimental | 27 | 5% | 0% | 14 |
Address terms |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | BIOMED RADIAT SCI | 176419 | 6% | 10% | 17 |
| 2 | 1 BRUCE ST | 108678 | 0% | 100% | 1 |
| 3 | CHEM CHEM MAT | 108678 | 0% | 100% | 1 |
| 4 | CYCLOTRON RADIOPHARMACEUT MBC 03 | 108678 | 0% | 100% | 1 |
| 5 | IBBT MEDISIP | 108678 | 0% | 100% | 1 |
| 6 | KOREA DRUG DEV PLATFORM USING RADIO ISOTOPE KDEPR | 108678 | 0% | 100% | 1 |
| 7 | KOREA DRUG DEV PLATFORM USING RADIOISOTOPE KDEPRI | 108678 | 0% | 100% | 1 |
| 8 | MINS 29 E VEDADO | 108678 | 0% | 100% | 1 |
| 9 | NEUROPEPTIDE RECEPT | 108678 | 0% | 100% | 1 |
| 10 | RADIODIAGN THER Y INTERNAL MED | 108678 | 0% | 100% | 1 |
Journals |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | NUCLEAR MEDICINE AND BIOLOGY | 44370 | 13% | 1% | 39 |
| 2 | BIOCONJUGATE CHEMISTRY | 10132 | 8% | 0% | 22 |
| 3 | CANCER BIOTHERAPY | 4572 | 1% | 2% | 2 |
| 4 | TUMOR TARGETING | 3746 | 0% | 3% | 1 |
| 5 | JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 3473 | 4% | 0% | 12 |
| 6 | CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2635 | 2% | 0% | 6 |
| 7 | CLINICS IN ONCOLOGY | 2049 | 0% | 2% | 1 |
| 8 | APPLIED RADIATION AND ISOTOPES | 1699 | 4% | 0% | 12 |
| 9 | JOURNAL OF NUCLEAR MEDICINE | 1503 | 4% | 0% | 12 |
| 10 | INTERNATIONAL JOURNAL OF NUCLEAR MEDICINE & BIOLOGY | 1475 | 1% | 1% | 2 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |